Testing Biospecimen Collection with Carboplatin for bilateral retinoblastoma

Inclusion

• +Patient must have newly diagnosed intraocular (localized) retinoblastoma and meet one of the following criteria:
• +Patient must be \< 18 years of age at enrollmentEnrolmentThe number of participants a study plans to include, or has included.Read more →
• +Unilateral Group D retinoblastoma with vitreous seeding; OR
• +Bilateral retinoblastoma with worst eye Group D, with vitreous seeding present and the contralateral eye is Group A-C; OR
• +Bilateral Group D retinoblastoma with at least one eye with vitreous seeding; OR
• +Bilateral retinoblastoma with one Group D eye with vitreous seeding and one Group E eye where the Group E eye has been enucleated prior to any therapy. Note exclusionExclusion criteriaThe things that would prevent someone from taking part.Read more → for high-risk features
• +Bilateral retinoblastoma with one Group D eye with vitreous seeding and one Group E eye where the Group E eye has not been enucleated prior to any therapy at the discretion of the treating physician. Note exclusion for patients with evidence of metastatic or extra orbital spread
• +Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2. Use Karnofsky for patients \> 16 years of age and Lansky for patients =\<16 years of age
• +Peripheral absolute neutrophil count (ANC) \>= 750/uL (must be performed within 7 days prior to enrollment unless otherwise indicated)
• +Platelet count \>= 75,000/uL (transfusion independent) (must be performed within 7 days prior to enrollment)
• +A serum creatinine based on age/sex as follows (must be performed within 7 days prior to enrollment; must be repeated prior to the start of protocolProtocolThe detailed plan a study must follow.Read more → therapy if \> 7 days have elapsed from their most recent prior assessment):
• +1 month to \< 6 months = 0.4 (male and female)
• +6 months to \< 1 year = 0.5 (male and female)
• +1 to \< 2 years = 0.6 (male and female)
• +2 to \< 6 years = 0.8 (male and female)
• +6 to \< 10 years = 1.0 (male and female)
• +10 to \< 13 years = 1.2 (male and female)
• +13 to \< 16 years = 1.5 (male) and 1.4 (female)
• +\>= 16 years = 1.7 (male) and 1.4 (female) OR - a 24-hour urine Creatinine clearance \>= 70 mL/min/1.73 m\^2 OR - a glomerular filtration rate (GFR) \>= 70 mL/min/1.73 m\^2. GFR must be performed using direct measurement with a nuclear blood sampling method OR direct small molecule clearance method (iothalamate or other molecule per institutional standard)
• +Note: Estimated GFR (eGFR) from serum creatinine, cystatin C or other estimates are not acceptable for determining eligibilityEligibility criteriaThe full list of requirements for taking part in a study.Read more →
• +For patients \< 1 month of age, serum creatinine levels must be \< 1.5 x the treating institution's creatinine upper limit of normal (ULN) for patients \< 1 month of age or the creatinine clearance or radioisotope GFR must be \>= 70 mL/min/1.73 m\^2
• +The threshold creatinine values were derived from the Schwartz formula for estimating GFR utilizing child length and stature data published by the Center for Disease ControlControl groupThe group a new treatment is measured against.Read more → (CDC)
• +Total bilirubin =\< 1.5 x upper limit of normal (ULN) for age (must be performed within 7 days prior to enrollment; must be repeated prior to the start of protocol therapy if \> 7 days have elapsed from their most recent prior assessment)
• +Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase \[ALT\]) =\< 135 U/L (must be performed within 7 days prior to enrollment; must be repeated prior to the start of protocol therapy if \> 7 days have elapsed from their most recent prior assessment)
• +Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L